Reda Rawi
Overview
Explore the profile of Reda Rawi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cale E, Shen C, Olia A, Radakovich N, Rawi R, Yang Y, et al.
Cell Rep
. 2024 Dec;
43(12):115010.
PMID: 39675002
Antibodies that target the gp120-gp41 interface of the HIV-1 envelope (Env) trimer comprise a commonly elicited category of broadly neutralizing antibodies (bNAbs). Here, we isolate and characterize VRC44, a bNAb...
2.
Lee M, Lu M, Zhang B, Zhou T, Katte R, Han Y, et al.
Comput Struct Biotechnol J
. 2024 Dec;
23:4192-4204.
PMID: 39640534
HIV-1 infection is initiated by the interaction between the gp120 subunit in the envelope (Env) trimer and the cellular receptor CD4 on host cells. This interaction induces substantial structural rearrangement...
3.
Reveiz M, Xu K, Lee M, Wang S, Olia A, Harris D, et al.
Front Immunol
. 2024 Nov;
15:1484029.
PMID: 39611147
Broadly neutralizing antibodies have been proposed as templates for HIV-1 vaccine design, but it has been unclear how similar vaccine-elicited antibodies are to their naturally elicited templates. To provide insight,...
4.
Wang H, Cheng C, Dal Santo J, Shen C, Bylund T, Henry A, et al.
Cell
. 2024 Oct;
187(25):7214-7231.e23.
PMID: 39471811
An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection...
5.
Ko S, Radecki P, Belinky F, Bhiman J, Meiring S, Kleynhans J, et al.
Nat Commun
. 2024 Aug;
15(1):7240.
PMID: 39174553
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these observations...
6.
Lee M, Lu M, Zhang B, Zhou T, Katte R, Han Y, et al.
bioRxiv
. 2024 Jul;
PMID: 39071380
HIV-1 infection is initiated by the interaction between the gp120 subunit in the envelope (Env) trimer and the cellular receptor CD4 on host cells. This interaction induces substantial structural rearrangement...
7.
Zhang B, Chuang G, Biju A, Biner D, Cheng J, Wang Y, et al.
Cell Rep
. 2024 May;
43(6):114285.
PMID: 38819987
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a plasma protein that controls cholesterol homeostasis. Here, we design a human PCSK9 mimic, named HIT01, with no consecutive 9-residue stretch in common...
8.
Xu J, Zhou T, McKee K, Zhang B, Liu C, Nazzari A, et al.
Adv Sci (Weinh)
. 2024 May;
11(26):e2309268.
PMID: 38704686
Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV-1, but their potency and breadth are less than optimal. This study describes the immunization of a llama with...
9.
Lederhofer J, Tsybovsky Y, Nguyen L, Raab J, Creanga A, Stephens T, et al.
Immunity
. 2024 Mar;
57(3):574-586.e7.
PMID: 38430907
Continuously evolving influenza viruses cause seasonal epidemics and pose global pandemic threats. Although viral neuraminidase (NA) is an effective drug and vaccine target, our understanding of the NA antigenic landscape...
10.
Ko S, Radecki P, Belinky F, Bhiman J, Meiring S, Kleynhans J, et al.
bioRxiv
. 2024 Feb;
PMID: 38313289
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the evolutionary processes underlying these observations...